Study confirms adding chemotherapy to surgery improves survival in advanced gastric cancer
(European Society for Medical Oncology) At the meeting Prof Sung Hoon Noh, a gastric surgeon from Yonsei University College of Medicine, Korea, presented 5-year follow-up from the phase III CLASSIC trial, which added combination chemotherapy to a standard surgical procedure called D2 gastrectomy. The chemotherapy regimen studied in the trial is called XELOX, which is a combination of the drugs capecitabine and oxaliplatin.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Eloxatin | Gastrectomy | Gastric (Stomach) Cancer | Gastroenterology | Health | International Medicine & Public Health | Study | Xeloda